Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Madeleine Duvic, Lauren C. Pinter-Brown, Francine M. Foss, Lubomir Sokol, Jeffrey L. Jorgensen, Pramoda Challagundla, Karen M. Dwyer, Xiaoping Zhang, Michael R. Kurman, Rocco Ballerini, Li Liu, Youn H. Kim

Blood (2015) 125 (12): 1883–1889.

https://doi.org/10.1182/blood-2014-09-600924

Published: 2015

Journal Articles

The Tumor Microenvironment in Mantle Cell Lymphoma (MCL): Novel Targets to Overcome Chemo-Resistance in MCL

Lan V Pham, PhD, Archito T. Tamayo, MS, Elizabeth Pogue, Gary Lu, MD, Pramoda Challagundla, Jeffrey L. Jorgensen, MD PhD, Liang Zhang, MD PhD, Michael Wang, MD, Richard J. Ford, MD PhD

Blood (2014) 124 (21): 494.

https://doi.org/10.1182/blood.V124.21.494.494

Published: 2014

Journal Articles

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Paolo Strati, Michael J. Keating, Susan M. O'Brien, Jan Burger, Alessandra Ferrajoli, Nitin Jain, Francesco Paolo Tambaro, Zeev Estrov, Jeffrey Jorgensen, Pramoda Challagundla, Stefan H. Faderl, William G. Wierda

Blood (2014) 123 (24): 3727–3732.

https://doi.org/10.1182/blood-2013-11-538116

Published: 2014

Includes: Supplemental data

Journal Articles

Analysis Of EphA3 Expression In Hematologic Malignancies By Quantitative PCR

John Woronicz, PhD, Jorge E. Cortes, MD, Jeffrey L. Jorgensen, MD, PhD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Pramoda Challagundla, Jairo Matthews, Jennifer Ho, Jackie M. Walling, MBChB, PhD, Geoffrey Yarranton, PhD, Naveen Pemmaraju, MD

Blood (2013) 122 (21): 4981.

https://doi.org/10.1182/blood.V122.21.4981.4981

Published: 2013

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Issa F. Khouri, MD, Rima M. Saliba, Ph.D., Pramoda Challagundla, Celina Ledesma, Martin Korbling, MD, Alison M Gulbis, PharmD, BCOP, Maria Guillermo-Pacheco, Sairah Ahmed, MD, Paolo Anderlini, MD, Qaiser Bashir, MD, Betul Oran, MD, Stefan O Ciurea, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD, Uday R Popat, MD, Elias Jabbour, MD, Richard E Champlin, MD, Jeffrey L. Jorgensen, MD, PhD

Blood (2013) 122 (21): 3349.

https://doi.org/10.1182/blood.V122.21.3349.3349

Published: 2013

Journal Articles

Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

Farhad Ravandi, Jeffrey L. Jorgensen, Deborah A. Thomas, Susan O’Brien, Rebecca Garris, Stefan Faderl, Xuelin Huang, Sijin Wen, Jan A. Burger, Alessandra Ferrajoli, Partow Kebriaei, Richard E. Champlin, Zeev Estrov, Pramoda Challagundla, Sa A. Wang, Rajyalakshmi Luthra, Jorge E. Cortes, Hagop M. Kantarjian

Blood (2013) 122 (7): 1214–1221.

https://doi.org/10.1182/blood-2012-11-466482

Published: 2013

Includes: Supplemental data

Journal Articles

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Madeleine Duvic, MD, Lauren Pinter-Brown, Francine Foss, MD, Lubomir Sokol, MD, PhD, Jeffrey Jorgensen, MD, PhD, Xiao Ni, MD, PhD, Pramoda Challagundla, MS, Meghali Goswami, BS, Karen Dwyer, Nehal Mohamed, PhD, Youn H Kim, MD

Blood (2012) 120 (21): 3697.

https://doi.org/10.1182/blood.V120.21.3697.3697

Published: 2012

Journal Articles

Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma

Xiao Ni, MD, PhD, Jeffrey L. Jorgensen, MD, PhD, Meghali Goswami, BS, Pramoda Challagundla, MS, William K Decker, PhD, Youn H. Kim, MD, Madeleine Duvic, MD

Blood (2011) 118 (21): 444.

https://doi.org/10.1182/blood.V118.21.444.444

Published: 2011

Journal Articles

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Farhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Charles Koller, Pramoda Challagundla, Sergernne York, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Deborah Thomas, Michael Keating, Hagop Kantarjian

Blood (2011) 118 (14): 3818–3823.

https://doi.org/10.1182/blood-2011-04-351502

Published: 2011

NARROW

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

The Tumor Microenvironment in Mantle Cell Lymphoma (MCL): Novel Targets to Overcome Chemo-Resistance in MCL

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

Analysis Of EphA3 Expression In Hematologic Malignancies By Quantitative PCR

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only